Biobanking potential for biomedical research in endocrinology

Biobanking is an actively developing scientific area that provides tools for conducting biomedical research, increasing the reliability and reproducibility of their results. In endocrinology, more and more attention is paid to the study of molecular and genetic markers of diseases for the selection of new points of influence in treatment, the development of targeted therapy and a strategy for personalized prevention. This approach is designed to solve the problems of endocrine disorders, their complications, causing significant damage to the individual and he population health, and reduce the financial burden of chronic endocrine disorders. To increase the reliability and reproducibility of research results, requirements for working with biological material should be strictly complied. The use of biobanking will increase the validity of data obtained in clinical trials in endocrinology. There are successful examples of Russian and foreign studies using the capabilities of biobanks aimed at studying diabetes, polycystic ovary syndrome, adenomas and other endocrine disorders. The article discusses the prospects for partnership with biobanks in the framework of endocrinology research. The purpose of this review is to analyze the literature to systematize knowledge for application of biobanking in biomedical research in the field of endocrinology.

1. Mikhailova AA, Nasykhova YuA, Muravyov AI, et al. Towards the creation of a unified glossary of Russian biobanks. Cardiovascular Therapy and Prevention. 2020;19(6):2710. (In Russ.) doi:10.15829/1728-8800-2020-2710.

2. Zohouri M, Ghaderi A. The Significance of Biobanking in the Sustainability of Biomedical Research: A Review. Iran Biomed J. 2020;24(4):206-13. doi:10.29252/ibj.24.4.206.

3. Coppola L, Cianflone A, Grimaldi AM, et al. Biobanking in health care: evolution and future directions. J Transl Med. 2019;17(1):172. doi:10.1186/s12967-019-1922-3.

4. Paskal W, Paskal AM, Dębski T, et al. Aspects of Modern Biobank Activity — Comprehensive Review. Pathol Oncol Res. 2018;24(4):771-85. doi:10.1007/s12253-018-0418-4.

5. Ershova AI, Ivanova AA, Kiseleva AV, et al. From biobanking to personalized prevention of obesity, diabetes and metabolic syndrome. Cardiovascular Therapy and Prevention. 2021; 20(8):3123. (In Russ.) doi:10.15829/1728-8800-2021-3123.

6. Zhu J, Pujol-Gualdo N, Wittemans LBL, et al. Evidence From Men for Ovary-independent Effects of Genetic Risk Factors for Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2022;107(4):e1577-87. doi:10.1210/clinem/dgab838.

7. Pärna K, Snieder H, Läll K, et al. Validating the doubly weighted genetic risk score for the prediction of type 2 diabetes in the Lifelines and Estonian Biobank cohorts. Genetic epidemiology. 2020;44(6):589-600. doi:10.1002/gepi.22327.

8. Crisafulli S, Luxi N, Sultana J, et al. Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinol. 2021;185(2):251-63. doi:10.1530/EJE-21-0216.

9. Aygun N, Uludag M. Pheochromocytoma and Paraganglioma: From Epidemiology to Clinical Findings. Sisli Etfal Hastan Tip Bul. 2020;54(2):159-68. doi:10.14744/SEMB.2020.18794.

10. Ebbehoj A, Stochholm K, Jacobsen SF, et al. Incidence and Clinical Presentation of Pheochromocytoma and Sympathetic Paraganglioma: A Population-based Study. J Clin Endocrinol Metab. 2021;106(5):e2251-61. doi:10.1210/clinem/dgaa965.

11. Hawley JM, Adaway JE, Owen LJ, et al. Development of a total serum testosterone, androstenedione, 17-hydroxyprogesterone, 11β-hydroxyandrostenedione and 11-ketotestosterone LC-MS/ MS assay and its application to evaluate pre-analytical sample stability. Clin Chem Lab Med. 2020;58(5):741-52. doi:10.1515/cclm-2019-0959.

12. Gangadharan C, Wills S, Vangala RK, et al. Biobanking for Translational Diabetes Research in India. Biores Open Access. 2020;9(1):183-9. doi:10.1089/biores.2019.0052.

13. Campbell LD, Astrin JJ, DeSouza Y, et al. The 2018 Revision of the ISBER Best Practices: Summary of Changes and the Editorial Team’s Development Process. Biopreserv Biobank. 2018;16(1):3- 6. doi:10.1089/bio.2018.0001.

14. Dollé L, Bekaert S. High-Quality Biobanks: Pivotal Assets for Reproducibility of OMICS-Data in Biomedical Translational Research. Proteomics. 2019;19(21-22):e1800485. doi:10.1002/pmic.201800485.

15. Fisher WE, Cruz-Monserrate Z, McElhany AL, et al. Standard Operating Procedures for Biospecimen Collection, Processing, and Storage: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Pancreas. 2018;47(10):1213-21. doi:10.1097/MPA.0000000000001171.

16. Sertkaya A, Wong HH, Jessup A, et al. Key cost drivers of pharmaceutical clinical trials in the United States. Clin Trials. 2016;13(2):117-26. doi:10.1177/1740774515625964.

17. Liu X, Wu S, Sun J, et al. Changes in clinical trials of endocrine disorder and metabolism and nutrition disorder drugs in mainland China over 2010-2019. Pharmacol Res Perspect. 2021;9(2):e00729. doi:10.1002/prp2.729.

18. van’t Riet E, Schram MT, Abbink EJ, et al. The Diabetes Pearl: Diabetes biobanking in The Netherlands. BMC Public Health. 2012;12:949. doi:10.1186/1471-2458-12-949.

19. Christensen H, Nielsen JS, Sørensen KM, et al. New national Biobank of The Danish Center for Strategic Research on Type 2 Diabetes (DD2). Clin Epidemiol. 2012;4:37-42. doi:10.2147/CLEP.S33042.

20. Wang M, Zhou T, Li X, et al. Baseline Vitamin D Status, Sleep Patterns, and the Risk of Incident Type 2 Diabetes in Data From the UK Biobank Study. Diabetes Care. 2020;43(11):2776-84. doi:10.2337/dc20-1109.

21. Wojtowicz W, Zabek A, Deja S, et al. Serum and urine 1H NMRbased metabolomics in the diagnosis of selected thyroid diseases. Sci Rep. 2017;7(1):9108. doi:10.1038/s41598-017-09203-3.

22. Sharma A, Varghese RT, Shah M, et al. Impaired Insulin Action Is Associated With Increased Glucagon Concentrations in Nondiabetic Humans. J Clin Endocrinol Metab. 2018;103(1):314- 9. doi:10.1210/jc.2017-01197.

23. Lu J, Hu S, Miccoli P, et al. Non-invasive diagnosis of papillary thyroid microcarcinoma: a NMR-based metabolomics approach. Oncotarget. 2016;7(49):81768-77. doi:10.18632/oncotarget.13178.

24. Solimena M, Schulte AM, Marselli L, et al. Systems biology of the IMIDIA biobank from organ donors and pancreatectomised patients defines a novel transcriptomic signature of islets from individuals with type 2 diabetes. Diabetologia. 2018;61(3):641-57. doi:10.1007/s00125-017-4500-3.

25. Li B, Wang X, Yang C, et al. Human growth hormone proteoform pattern changes in pituitary adenomas: Potential biomarkers for 3P medical approaches. EPMA J. 2021;12(1):67-89. doi:10.1007/s13167-021-00232-7.

26. Lydia Kynast K, Volk N, Fleming T, et al. Diabetes-Associated Biobanking: More Topical Than Ever? Exp Clin Endocrinol Diabetes. 2017;125(9):603-9. doi:10.1055/s-0042-123039.

27. Pan B, Wang A, Pang J, et al. Programmed death ligand 1 (PD-L1) expression in parathyroid tumors. Endocr Connect. 2019;8(7):887-97. doi:10.1530/EC-19-0163.

28. Tierney JF, Vogle A, Finnerty B, et al. Indoleamine 2,3-Dioxygenase-1 Expression in Adrenocortical Carcinoma. J Surg Res. 2020;256:90-5. doi:10.1016/j.jss.2020.06.016.

29. Fussey JM, Beaumont RN, Wood AR, et al. Does Obesity Cause Thyroid Cancer? A Mendelian Randomization Study. J Clin Endocrinol Metab. 2020;105(7):e2398-407. doi:10.1210/clinem/dgaa250.

30. Welsh S, Peakman T, Sheard S, et al. Comparison of DNA quantification methodology used in the DNA extraction protocol for the UK Biobank cohort. BMC Genomics. 2017;18(1):26. doi:10.1186/s12864-016-3391-x.

31. Olson JE, Ryu E, Hathcock MA, et al. Characteristics and utilisation of the Mayo Clinic Biobank, a clinic-based prospective collection in the USA: cohort profile. BMJ Open. 2019;9(11):e032707. doi:10.1136/bmjopen-2019-032707.

32. Parichehreh-Dizaji S, Samimi H, Asadolahpour E, et al. Establishment of biobank facility at Endocrinology and Metabolism Research Institute of Iran: experiences, challenges, and future outlook. J Diabetes Metab Disord. 2021;20(1):1081-4. doi:10.1007/s40200-021-00781-8.

33. Hall MA, King NM, Perdue LH, et al. Biobanking, consent, and commercialization in international genetics research: the Type 1 Diabetes Genetics Consortium. Clin Trials. 2010;7(1 Suppl):S33-45. doi:10.1177/1740774510373492.

34. Santana Del Pino A, Medina-Rodríguez N, Hernández-García M, et al. Spanish Type 1 Diabetes Genetics Network, T1DGC. Is HLA the cause of the high incidence of type 1 diabetes in the Canary Islands? Results from the Type 1 Diabetes Genetics Consortium (T1DGC). Endocrinol Diabetes Nutr. 2017;64(3):146-51. doi:10.1016/j.endinu.2016.12.003.

35. Marchand L, Li M, Leblicq C, et al. Monogenic Causes in the Type 1 Diabetes Genetics Consortium Cohort: Low Genetic Risk for Autoimmunity in Case Selection. J Clin Endocrinol Metab. 2021;106(6):1804-10. doi:10.1210/clinem/dgab056.

36. van Oort S, Rutters F, Warlé-van Herwaarden MF, et al. Characteristics associated with polypharmacy in people with type 2 diabetes: the Dutch Diabetes Pearl cohort. Diabet Med. 2021;38(4):e14406. doi:10.1111/dme.14406.

37. Christensen DH, Nicolaisen SK, Ahlqvist E, et al. Type 2 diabetes classification: a data-driven cluster study of the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) cohort. BMJ Open Diabetes Res Care. 2022;10(2):e002731. doi:10.1136/bmjdrc-2021-002731.

38. Christensen DH, Nicolaisen SK, Berencsi K, et al. Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort of newly diagnosed patients with type 2 diabetes: a cohort profile. BMJ Open. 2018;8(4):e017273. doi:10.1136/bmjopen-2017-017273.

39. Anisimov SV, Ahmerov TM, Balanovskij OP, et al. Biobankirovanie. Nacional’noe rukovodstvo. Moskva: Izdatel’stvo TRIUMF, 2022. s. 308. (In Russ.) ISBN: 978-5-93673-322-2.

40. Hewitt RE, Grizzle WE, Watson PH, et al. Biobank and Expertise Networks. In: Hainaut P, Vaught J, Zatloukal K Biobanking of Human Biospecimens: Principles and Practice. Springer International Publishing. 2017:111-35. doi:10.1007/978-3-319-55120-3_7.

41. Lähteenmäki J, Vuorinen AL, Pajula J, et al. Integrating data from multiple Finnish biobanks and national health-care registers for retrospective studies: Practical experiences. Scand J Public Health. 2022;50(4):482-9. doi:10.1177/14034948211004421.

42. Rubinstein YR, Posada de la Paz M, Mora M. Rare Disease Biospecimens and Patient Registries: Interoperability for Research Promotion, a European Example: EuroBioBank and SpainRDR-BioNER. Adv Exp Med Biol. 2017;1031:141-7. doi:10.1007/978-3-319-67144-4_7.

43. Olesen SS, Svane HML, Nicolaisen SK, et al. Clinical and biochemical characteristics of postpancreatitis diabetes mellitus: A cross-sectional study from the Danish nationwide DD2 cohort. J Diabetes. 2021;13(12):960-74. doi:10.1111/1753-0407.13210.

44. Simeon-Dubach D, Watson P. Biobanking 3.0: evidence based and customer focused biobanking. Clin Biochem. 2014;47(4- 5):300-8. doi:10.1016/j.clinbiochem.2013.12.018.